INTERNATIONAL CANNABIS
AND CANNABINOIDS INSTITUTE:
CENTER OF EXCELLENCE

icci-symbol-white

The ICCI founders share combined experience that includes clinical and basic research, direct patient advocacy, legislative efforts and studies, government relations, advisory and administration, medical informatics, the creation of product safety protocols such as quality control/quality assurance standards and laboratory analysis for the cultivation, manufacturing and distribution of cannabis products and global entrepreneurship. Our unique position will leverage unparalleled resources and experience to create this global resource. A portion of revenue generated from commercial services and products will be dedicated to ASA1), KOPAC2) and IMCPC3).


  1. Americans for Safe Access; US-based organization that aims to ensure safe and legal access to cannabis for therapeutic uses and research
  2. The Patient Association for Cannabis Treatment, Czech Republic
  3. International Medical Cannabis Patients Coalition

ICCI Projects

  1. International Call for Standardization of Data in Cannabis Research and Adverse Event Reporting
  2. Global Scientific-Based Biomedical, Life Science and Policy Research Priority Mapping and Management
  3. Cannabis Metabolome Project
  4. Cannadata Project
  5. GMP/GAP/GLP Cannabis Product Standards

ICCI Products

RESEARCH TOOLS

Despite the global popularity of cannabis and cannabinoid research, there is currently a lack of research tools for scientists to study cannabis and the human body including (but not limited to) new analytical methods, cell lines, antibodies and reagents, diagnostic markers of disease, and next-generation hardware and software for manufacturing and product development.

WORKFORCE AND PROFESSIONAL DEVELOPMENT

ICCI will need skilled and dedicated staff, such as people with vocational aptitude and specialization. The ICCI will offer unique opportunities for graduates and undergraduate students studying in the fields of manufacturing, food processing, horticulture and other related quality control/quality assurance programs. These opportunities may lead to the development of new bachelor degree programs for students, and an abundance of Ph.D. projects at ICCI.

Principal areas of the
ICCI’s efforts

PATENT AND IP DEVELOPMENT

Patent development and application, incubation of start-ups, device hardware and software engineering, delivery system development, formulations, processes and the like.

Metabolomics Tools

The ICCI will build a biological library of unique strain metabolomics that characterize and catalog the full spectrum of compounds (known and unknown) from each cannabis specimen that is analyzed. This library will be a unique tool for matching metabolomic profiles with desired indications for optimal clinical trial design, recommendations for personalized treatment methods and agricultural sciences.

BIG DATA TOOLS AND SURVEYS FOR ORIENTING RESEARCH AND PERSONALIZED TREATMENT

The ICCI will utilize big data platforms and tools to provide a variety of research services for product manufacturers and distributors, laboratories and research institutes, medical professionals/individual patients, universities and private institutions.

INTERNATIONAL PATIENT FOCUSED CERTIFICATION

Patient Focused Certification (PFC) represents the consensus of the world’s leading experts on cannabis, hemp and botanical product regulations and holds government contracts for providing these services. PFC certifies compliance with GMP, GAP, and GLP standards for medical cannabis products and services based on protocols from governments, the American Herbal Products Association, the Hemp Industry Association and American Herbal Pharmacopoeia. The ICCI will modify these services and offer them to the international market.

CLINICAL RESEARCH SERVICES

In partnership with Czech institutions, the ICCI will design, manage and provide services for clinical trials for both public and private endeavors. The ICCI will incorporate new research and innovative techniques to meet the needs unique to the design, management and data analysis of cannabis-related clinical trials.

Benjamin Z. Bronfman

ICCI Director of International Business Development

Ben Bronfman first became interested in the cannabis space seven years ago when he moved to Los Angeles, CA. After surveying the industry, he decided to join the board of Americans for Safe Access. At that time there were 16 States which had passed Cannabis laws. Mr. Bronfman has been one of ASA’S most engaged board members. In addition to his work with ASA, Bronfman partnered with various Silicon Valley investors to help elect Kamala Harris, The Attorney General of California, who was locked in a standoff election with Steve Cooley in 2010. This helped ensure that the laws in the country’s largest cannabis market would not be reversed.

Mr. Bronfman is an entrepreneur, environmentalist and Grammy-nominated musician/producer based in New York City. Mr. Bronfman is managing director of Global Thermostat, which he co- founded with Columbia University economist Graciela Chichilinsky and fellow Columbia Professor Peter Eisenberger. Mr Bronfman was responsible for securing the firm’s $100M valuation and has orchestrated various business and strategic partnerships for the firm.  Bronfman is on the board of several organizations including Pioneer Works, a center for art and innovation in Red Hook, Brooklyn.. Mr. Bronfman also has positions in various technology start ups and was recently the recipient of Global Green’s impact Entrepreneur Award alongside the Clinton Foundation.

Pavel Kubů, MD

ICCI Chief Executive Officer

Pavel Kubů is an expert in the fields of medical informatics and addictology. In 2001, he graduated in general medicine with a focus on disease prevention and public health from the Third Faculty of Medicine, Charles University.

Since 2005 he has been working for the Intel Corporation as a Business Development Manager, leading projects of the Intel World Ahead Programme for Healthcare in Central and Eastern Europe and Education in the Czech Republic and Slovakia.

In 2006 he was appointed as chair of the Ethics Commission at the National Monitoring Centre for Drugs and Addiction.

Pavel has served since 2007 as a board member of the Czech National Forum for eHealth, from 2012 to 2015 as a member of the steering committee of the Czech Healthcare Forum and since 2013 as a board member of the medical cannabis patients’ organisation KOPAC. In these non-profit NGOs he is primarily devoted to the education of healthcare professionals, patients and caregivers and support for the research and development of new treatment and preventive methods.

Since 2011 he has led the implementation of medical strategy at the company ELON MEDICAL s.r.o., devoted to wearable plastic electronics for new treatment methods using printed light devices.

In 2014 he became a cofounding member of Konomed s.r.o., a company that focuses on research and development in the field of medical cannabis.

Steph Sherer

ICCI Director of Innovations

Founder and Executive Director of Americans for Safe Access, founding member of International Medical Cannabis Patients Coalition (IMCPC). Steph has become the foremost international leader and expert on medical cannabis patient advocacy and, alongside the American Herbal Products Association (AHPA), has created the first industry standards in the areas of Distribution, Cultivation, Analytics, and Manufacturing, Packaging, and Labeling.

Tomáš Zábranský, MD, PhD

ICCI Chief Scientist

Graduated from the Medical Faculty of Palacky University, Olomouc in 1993 (M.D.); he received his Ph.D in epidemiology, hygiene, and preventive medicine from the same university in 2001. In 2003–4, he was an H. H. Humphrey/NIDA Research Fellow at Johns Hopkins Bloomberg School of Public Health, USA, professionally affiliated with the Center for Drug Policy Research of the RAND Corp. think-tank. Since 2014, he has served as Advisor on Drug Policy to the Czech Prime Minister and as the Envoy of the Czech Minister of Health for the Implementation of Medical Cannabis into the Czech Medical System and for Illegal Drug Issues. Tomáš works as an expert in drug epidemiology and monitoring of the drug situation in numerous UN and EU projects. Recently, in 2015, he was elected by the EU Parliament as an (Independent) Member of the Management Board of the European Monitoring Centre for Drugs and Addictions.

ICCI Media contact

Jakub Vecerka

Jakub Vecerka works in ICCI as PR & Marketing manager. He graduated from University of Economics in Prague and his experinces in public relations contain Czech Republic Ministry of Health,  City Quater of Prague 5, GECO a.s., Vitkovice a.s., MSD Animal Health, Sprinx Systems a.s..

Contact informations: jakub.vecerka@icci.science or GSM: +420 603 185 441

 

 

Alexandra Šulcová, Professor of Pharmacology,M.D., P.D., FCMA, FECNP, FCINP

Professor of Pharmacology, FCMA, FECNP, FCINP, Masaryk University, Brno, Czech Republic. After her graduation as M.D. she started her carrier in Pharmacology at the Faculty of Medicine, Masaryk University. She has served as a Professor of Pharmacology and Head of the Department of Pharmacology. She has extensive and varied administrative experience, serving as a member of the Scientific Council and the Vice-Dean for Foreign Relations. In 2011, she moved to the position of Leader of the Research Group “Experimental and Applied Neuropsychopharmacology” at the Central European Institute of Technology (CEITEC), Masaryk University. In research, she is dedicated to neuropsychopharmacology since her Ph.D. studies completed at the Pharmacological Institute Academy of Sciences, Prague, Czech Republic. The most cited papers deal with cannabinoids (collaboration with prof. R. Mechoulam`s Jerusalem laboratory) and methamphetamine studies. In 2013, Dr. Sulcova was given the “Milada Paulova Award in Experimental and Clinical pharmacology and Toxicology” by the Czech Minister of Education. In 2014 she was elected as Fellow of the Czech Medical Academy (FCMA). Dr. Sulcova, has been and is, a member of committees of several national and international scientific societies. She is an Honorary Member of the 52 years old Czech Neuropsychopharmacological Society (CNPS), serving as the President in 1999-2000. Her experience is also proved with her membership in the Executive Committees in the Czech Society for Experimental and Clinical Pharmacology and Toxicology, European Behavioural Pharmacology Society (EBPS), European College of Neuropharmacology (ECNP). In 2010-2014 she was elected and served for the International College of Neuropsychopharmacology (CINP) Office of Vice President and for the CINP 2016 elections Dr. Sulcova accepted the nomination as a candidate for the Presidential post.

As. Prof. Marian Hajduch MD, PhD

has been a principal investigator and investigator or clinical site manager in 12 clinical trials. Sucessfully established a major cancer research foundation in the Czech Republic. He has also participated in the creation of a national network for personalized medicine and cancer management policies. He is chairing the Board of National Directors, and the Czech National Director for European Translational Medicine Infrastructure (EATRIS).

Doc. RNDr. Lumír Ondřej Hanuš, DrSc., Dr.h.c.mult.

is a Czech analytical chemist and a leading authority in the field of cannabis research. In 1992, he and William Anthony Devane isolated and first described the structure of anandamide, an endogenous cannabinoid neurotransmitter. Lumír Ondřej Hanuš is a research fellow at the Hebrew University in Jerusalem, Israel. He has been awarded honorary Doctoral degrees – Chemiae Doctor honoris causa (2007) and Medicinae Doctor honoris causa (2011), the Hanuš Medal (2005), the Addictology Award (2012), and Olomouc City Award (2013). His major research interests are the chemistry of natural products (the isolation and identification of new compounds from plants and animals) and the testing of compounds for biological activity.

Dr. Pavel Pachta

Drug Regulatory Control Consultant, former Deputy Secretary of the International Narcotics Control Board (INCB), former Chief of the Narcotics Control and Estimates Section of the Secretariat of INCB at the United Nations Office on Drugs and Crime (UNODC), contributor to several UN and WHO publications.

Ing. Petr Kaštánek, PhD

Biotechnologist and Biochemical Engineer, graduated from University of Chemistry and Technology in Prague. Director of BIORAF – Biorefinery Research Centre of Competence (complex biomass treatment and utilization), CEO at EcoFuel Laboratories Ltd. (biotechnology, extraction and bioreactors) and BIOCEN Laboratories Ltd. (bioactive compounds for nutraceuticals and cosmetics). Membership: Czech biofuel platform, CEBIO – Czech Biotechnology platform, Who is Who in World 2011, 2000 outstanding intellectuals of 21st century 2011. Grand Prize “Eco-Praha 1995”, co-author of technology awarded “Innovation of the Year 2001”. Scientific stays at H. C. Orsted Institute in Copenhagen and Max Planck Institute in Dortmund. Research activities in areas of bioreactor construction, biotechnology of microalgae and isolation of bioactive compounds from nature sources. Author of over 15 patents. Currently teaching Bioengineering at University of Chemistry and Technology Prague.

Jahan Marcu, PhD

is the senior scientist for Americans for Safe Access (ASA) and the Chief Auditor of the ASA’s Patient Focused Certification program. Founder and Vice-chair of the American Chemical Society’s Cannabis sub-division. Member and Board of Directors of the International Association for Cannabinoids as Medicine. Author of the American Herbal Pharmacopeia Cannabis Monograph. Serves on multiple expert government and trade association committees and scientific organizations, including the American Herbal Products Association (AHPA), American Society of Pharmacognosy, American Oil Chemist Society (AOCS), American Organization of Analytical Chemists (AOAC), International Medical Cannabis Patients Coalition (IMCPC), and others.

Justin Fischedick, PhD

is the founder and senior analytical chemist at Excelsior Analytical Laboratory. He studied the cannabis metabolome and terpenes of the plant at Leiden University in Holland, beginning in 2008. He worked at the University of Washington State studying the biosynthesis of terpenes in the cannabis plant from 2013–2015.

Prof. Petr Arenberger, MD, Ph.D

Chair of the Dermatovenereology Clinic, Third Faculty of Medicine, Charles University in Prague. President of the Czech Dermatovenerology Society within the Czech Medical Association of J. E. Purkyne. Secretary of the European Board of Dermatovenereology of the UEMS.

MUDr. Jan HAJER, Ph.D

Undergraduate education:

1989-1995 –MD in General Medicine at the 3rd Medical faculty of Charles university in Prague

1985-1989 – High School Jateční, Ústí nad Labem

 

Higher education and qualifications:

2002 – specialization in the field of gastroenterology

1995 – 2001 – PhD study in the field of Human physiology and pathophysiology

1999 – I. degree attestation in the field of Internal Medicine

 

Past and current employment:
2015 – head of the gastroenterology division of the II. Internal Medicine Clinic of the FNKV and 3rd Medical faculty of Charles university in Prague

1995 – now – physician at the II. Internal Medicine Clinic of the FNKV and 3rd Medical faculty of Charles university in Prague

 

Teaching experience:

2000 – now – assistant professor in the field of internal medicine at the at the 3rd Medical faculty of Charles university in Prague

2000-2004 – assistant professor in the field of cellular and molecular biology

 

International experience:

1995 – Molecular genetics department, prof.Mittermayer, Linz- Krankenhaus der Elisabetethen
1997 – Molecular biology department, prof.Schackert,  Medizinische Facultät TU Dresden

 

Awards

Czech Society of Gastroenterology supported by the Leciva company – project Molecular genetic diagnostics of HNPCC – 1997

Preis der MGG für osteuropäische Gastroenterologen – study Novel germline mutations of hMLH1 gene in czech patients with colorectal cancer – 2000

Prof. Dr. Jana Hajšlová

Institute of Chemical Technology, Prague – Department of Food Chemistry and Analysis, Member of the EU Scientific Committee on Emerging and Newly Identified Health Risks, SCENIHR (Health & Consumer Protection DG), Member of the International Editorial Board – Journal of Food Additives and Contaminants and member of the WHO National Contact Point for the Global Environmental Monitoring Program (GEMS/Food EURO).

Prof. Jan Žaloudík, MD, PhD

Director of the Masaryk Memorial Cancer Institute, Member of the Senate of the Parliament of the Czech Republic and the chair of its Committee on Health and Social Policy. Chair of the Section for Surgical Oncology of the Czech Surgical Society of the Czech Medical Association of J.E. Purkyne. Czech Republic representative at the World Federation of Surgical Oncology Societies. In 1999–2002, he was vice-dean for science and research, and in 2003–2010, he was the dean of the Medical Faculty of Masaryk University in Brno.

Prof. Jiří Horáček, MD, PhD

Professor of Psychiatry at the Third Faculty of Medicine, Charles University in Prague. He holds a degree in psychiatry and psychotherapy. He is currently the Deputy Director for Science at the National Institute of Mental Health, Czech Republic. He is both the editor of several books and the author of more than 100 scientific articles. Prof. Jiří Horáček has received several national and international psychiatric awards from the International Pharmaco-EEG Society (Werner Hermann Memorial Award), the Czech Neuropsychopharmacological Society and ECNS-ISNIP.

Prof. JUDr. Pavel Šturma, DrSc.

Professor and Head of the Department of International Law, Charles University in Prague, Faculty of Law, and coordinator of the Research Centre for Human Rights (UNCE). Senior Research Fellow of the Institute of Law, Czech Academy of Sciences. Member of the UN International Law Commission. President of the Czech Society of International Law. Editor-in-Chief of the Czech Yearbook of Public & Private International Law. He is author or co-author of 16 books and more than 140 articles and studies in International Law. The main topics of his research include human rights, the codification of international law, international responsibility and international criminal law.

Prof. Richard Rokyta, MD, PhD

As a founding member of the Czech Medical Academy, he was its first vice-chair and now serves as its chair. Vice-Dean Emeritus of the Third Faculty of Medicine, Charles University in Prague. In 1982–2009, he was the head of the Department of Normal, Pathological, and Clinical Physiology of the Third Faculty of Medicine, Charles University in Prague, and he is a Teaching Professor of physiology and pathological physiology there. He co-established the system of postgraduate studies at Charles University and the Czech Neuropsychopharmacological Society. He has been honored, inter alia, by the award of a Chevalier Des Palmes Academiques by the French Prime Minister.

Prof. Robert Gürlich, MD

Chairman of the Surgery Clinic, Charles University in Prague, Third Medical Faculty. Member of the Scientific board of the Charles University in Prague, Third Medical Faculty.

Prof. Tomáš Zima, MD, PhD, MBA

Rector of Charles University in Prague. He chairs the Scientific Council of the Czech Science Foundation and is a member of the Scientific Council of Charles University in Prague. Head of the Institute of Medical Biochemistry and Laboratory Medicine, First Faculty of Medicine, Charles University and General University Hospital Prague. Member of the Executive Board of the European Federation of Clinical Chemistry and Laboratory Medicine, vice-president of the International Society of Oncology and Biomarkers Board, and President of the European Society for Biomedical Research on Alcoholism.

Steph Sherer

ICCI Director of Innovations

Founder and Executive Director of Americans for Safe Access, founding member of International Medical Cannabis Patients Coalition (IMCPC). Steph has become the foremost international leader and expert on medical cannabis patient advocacy and, alongside the American Herbal Products Association (AHPA), has created the first industry standards in the areas of Distribution, Cultivation, Analytics, and Manufacturing, Packaging, and Labeling.

Tomáš Zábranský, MD, PhD

ICCI Chief Scientist

Graduated from the Medical Faculty of Palacky University, Olomouc in 1993 (M.D.); he received his Ph.D in epidemiology, hygiene, and preventive medicine from the same university in 2001. In 2003–4, he was an H. H. Humphrey/NIDA Research Fellow at Johns Hopkins Bloomberg School of Public Health, USA, professionally affiliated with the Center for Drug Policy Research of the RAND Corp. think-tank. Since 2014, he has served as Advisor on Drug Policy to the Czech Prime Minister and as the Envoy of the Czech Minister of Health for the Implementation of Medical Cannabis into the Czech Medical System and for Illegal Drug Issues. Tomáš works as an expert in drug epidemiology and monitoring of the drug situation in numerous UN and EU projects. Recently, in 2015, he was elected by the EU Parliament as an (Independent) Member of the Management Board of the European Monitoring Centre for Drugs and Addictions.

Viktor Mravčík, MD, PhD

Head of the Czech National Monitoring Centre for Drugs and Addictions, epidemiologist and biostatistician. Member of the board of the Society for Addictive Diseases of the Czech Medical Association, former Vicespokesman of the EU-wide network of National Monitoring Centers on Drugs (REITOX). Dr. Mravcik is the main author and editor of the Czech Annual Reports on Drug Situation and author and co-author of more than 100 scientific papers and chapters in monographs.

ICCI Strategic Alliances

Project partners that are ready for cooperation in different fields of activities

Blog and press releases

18.10. 2016

Patient Focused Certification training course

We are warmly inviting you to the first European seminar of Patient Focused Certification (PFC) which is as a step within PFC global expansion. PFC is aiming to ensure quality in the cultivation –…

All articles >

ICCI Strategic Alliances

Project partners that are ready for cooperation in different fields of activities